Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May 7;16(17):2163-9.
doi: 10.3748/wjg.v16.i17.2163.

Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX

Xue-Feng Ni  1 , Chang-Ping Wu, Jing-Ting Jiang
Affiliations

Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX

Xue-Feng Ni et al. World J Gastroenterol. .

Abstract

Aim: To explore if vascular endothelial growth factor receptor-3 (VEGFR-3) and carcinoembryonic antigen (CEA) can predict overall survival in advanced gastric cancer.

Methods: VEGFR-3 level was assessed by enzyme-linked immunosorbent assay, and CEA was assessed by chemiluminescence immunoassay in the sera of 81 advanced gastric cancer patients before treatment with oxaliplatin plus 5-fluorouracil and folinic acid.

Results: Median survival time in patients with a low serum VEGFR-3 level was significantly longer than in those with a higher VEGFR-3 level (15.4 mo vs 7.7 mo, P < 0.001). Patients with a low CEA level had a longer survival than those with a higher CEA level (15.8 mo vs 8.6 mo, P < 0.001). Thirty-nine patients with low VEGFR-3 and low CEA levels had a median survival of 19.7 mo (P = 0.0006). The hazard ratio for patients with a high VEGFR-3 level was 2.443 (P = 0.002).

Conclusion: High serum VEGFR-3 level is correlated significantly with poor survival. In patients with a high serum level of VEGFR-3, alternative chemotherapy regimens should be considered.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier estimates of overall survival by vascular endothelial growth factor receptor-3 (VEGFR-3) levels (n = 81, low VEGFR-3: 52; high VEGFR-3: 29).
Figure 2
Figure 2
Kaplan-Meier estimates of overall survival according to VEGFR-3 levels in patients. A: Patients with high carcinoembryonic antigen (CEA) levels (n = 24, high CEA and low VEGFR-3: 13, high CEA and high VEGFR-3: 11); B: Patients with low CEA levels (n = 57; low CEA and low VEGFR-3: 39; low CEA and high VEGFR-3: 18).
See this image and copyright information in PMC

References

    1. Inoue M, Tsugane S. Epidemiology of gastric cancer in Japan. Postgrad Med J. 2005;81:419–424. - PMC - PubMed
    1. Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol. 2006;12:17–20. - PMC - PubMed
    1. Gaspar MJ, Arribas I, Coca MC, Díez-Alonso M. Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. Tumour Biol. 2001;22:318–322. - PubMed
    1. Mihmanli M, Dilege E, Demir U, Coskun H, Eroglu T, Uysalol MD. The use of tumor markers as predictors of prognosis in gastric cancer. Hepatogastroenterology. 2004;51:1544–1547. - PubMed
    1. Ychou M, Duffour J, Kramar A, Gourgou S, Grenier J. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers. 2000;16:105–110. - PMC - PubMed

MeSH terms

Supplementary concepts